TrialBlood advances2024

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for transplant-ineligible myeloma: AMaRC 03-16.

Peter Mollee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.